Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
SOBERANA CENTRO
View latest
Revisiones
Comparando dos revisiones:
19 Diciembre 2022 - 12:15pm
por FINLAY
19 Diciembre 2022 - 12:30pm
por FINLAY
< diferencia anterior
Cambios a
Authorization date
-
+
2021-07-23 00:00:00
Cambios a
Reference number
-
In process
+
0.5.022.21BA
Cambios a
Recruitment status
-
Pending
+
Complete
Revisión de 19 Diciembre 2022 - 12:30pm
SOBERANA CENTRO
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Acronym of Public Title:
SOBERANA CENTRO
Scientific title:
Phase II randomized, double-blind, parallel-group, adaptive and multicenter study to evaluate the non-inferiority of the immune response in adults of the prophylactic anti-SARS-CoV-2 vaccine candidate FINLAY-FR-1 compared to FINLAY-FR-02 in Heterologous Two Dose and One Boost Dose Schedules with FINLAY-FR-1A. (COVID-19)
Acronym of Scientific Title:
SOBERANA CENTRO
Secondary indentifying numbers:
IFV/COR/14
Issuing authority of the secondary identifying numbers:
Finlay Vaccine Institute (IFV)
Primary sponsor:
Finlay Vaccine Institute (IFV)
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Finlay Vaccine Institute; Cuban Fund for Science and Innovation (FONCI) of Ministry of Science, Technology and Enviroment (CITMA)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Center for State Control of Drugs, Medical Devices and Equipment (CECMED)
Authorization date :
23/07/2021
Reference number:
0.5.022.21BA
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Maria
Midle name:
Eugenia
Last name:
Toledo Romani
Medical Specialty :
First Degree Specialist Physician in Integral General Medicine. Doctor of Medical Science
Affiliation:
Institute of Tropical Medicine "Pedro Kouri"
Postal address:
Novia del Mediodia avenue, KM 6 1/2, La Lisa
City:
Havana
País:
Cuba
Zip Code:
11400
Telephone:
+53-72020427
Email address:
mariaeugenia@ipk.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Cienfuegos, Palmira. Manuel Piti Fajardo Polyclinic. Laydami Cardenas Gonzalez, MD. First Degree Specialist in Integral General Medicine
Cienfuegos, Cruces. Manuel Piti Fajardo Polyclinic. Belkys Elena Morales Hernandez, MD. First Degree Specialist in Integral General Medicine
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Complete
Date of first enrollment:
26/07/2021
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
COVID-19
Health condition(s) code:
Disease Prevention
Coronavirus Infections
SARS Virus
Coronaviridae Infections
Betacoronavirus
Healthy Volunteers
Health condition keyword:
COVID-19
SARS-CoV2
Intervention(s):
Group 1 (experimental) FINLAY-FR-1: 50 µg RBD + 20 µg EMV / alumina; 0.5 mL, Intramuscular (IM), 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 µg dRBD / alumina, 0.5 mL, Intramuscular (IM). Presentation: Vial with single dose. Group 2 (experimental) FINLAY-FR-2: 25 µg of RBD-TT / alumina; 0.5 mL, Intramuscular (IM), 0-28 days + Booster dose day 56 FINLAY-FR-1A: 50 µg dRBD / alumina, 0.5 mL, Intramuscular (IM). Presentation: Vial with single dose.
Intervention code:
Immunogenicity, Vaccine
Immunotherapy, Active
Vaccination
Injections, Intramuscular
Intervention keyword:
SOBERANA
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Concentration of specific anti-RBD IgG antibodies (Percentage of subjects with seroconversion 4-fold to pre-vaccination). Measurement time: Day 0, 42 and 70. Moreover, in a subset of subjects’ samples with seroconversion, the outcome will measure at months 4, 8 and 12 after completing scheme vaccination.
Key secondary outcomes:
1) Serious Adverse Events-SAE (It will measure as: -Occurrence of the SAE (Yes, No), - Duration (Time from start date until end date of event), -Description of the event, Result (Recovered, Recovered with squeals, Persists, Death, Unknown), - Causality (Causal association consistent with vaccination, Undetermined, Inconsistent causal association with vaccination, not classifiable). Measurement time: daily for 28 days after each dose. 2) Solicited Local and systemic Adverse Events (AE) (They will measure as: -Occurrence of the AE (Yes, No), Duration (Time from start date until end date of event), -Intensity of the AE (mild, moderate, severe), -Severe (Serious, not serious), -Result (Recovered, Recovered with sequelae, Persists, Death, Unknown), -Causation (causal association consistent with vaccination, Indeterminate, causal association inconsistent with vaccination, not classifiable)). Measurement time: daily for 3 days after each dose. 3) Unsolicited Adverse Events (AE) (They will measure as: Description of the AE (name of the event), Duration (Time from start date until end date of event), -Intensity of the AE (mild, moderate, severe), -Severe (Serious, not serious) , -Result (Recovered, Recovered with sequelae, Persists, Death, Unknown), -Causality (causal association consistent with vaccination, Undetermined, causal association inconsistent with vaccination, not classifiable)). Measurement time: daily for 28 days after each dose. 4) % ACE2-RBD inhibition: Measurement time: Day 42 and 70 (It is measured on the total of subjects’ samples with seroconversion). 5) Molecular neutralization titer. Measurement time: Day 42 and 70 (It is measured on the total of subjects’ samples with seroconversion). 6) Neutralizing antibody titer: Measurement time Day 42 and 70 (It is measured on a subset of samples).
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
19 years
Maximum age:
80 years
Inclusion criteria:
1) Subjects aged between 19 and 80 years. 2) Subjects who give their informed consent to participate in the study in writing. 3) Women of childbearing age who use contraceptive methods during the study and are willing to use them up to three months after the corresponding vaccination schedule has concluded.
Exclusion criteria:
1) Subjects with acute febrile or infectious disease in the seven days prior to the administration of the vaccine or at the time of its application. 2) Subjects with diminished mental faculties for decision making. 3) Subjects with a history of known hypersensitivity to any of the components of the formulation. 4) Previous history of SARS-CoV-2 infection or subjects positive to the antigen test at the time of inclusion. 5) Subjects previously vaccinated against SARS-CoV-2. 6) Application of vaccines containing tetanus toxoid or the VA-MENGOC-BC vaccine in the last three months. 7) Application of any other vaccine of the extended immunization schedule in the last 30 days. 8) Treatment with immunomodulators in the last 30 days, considering steroids (except topical and inhaled), cytostatics, interferon, HeberFERON, immunoferon, transfer factor, biomodulin T, any gamma globulin, levamisole, thymosin or other drugs with immunomodulatory action. In addition, those people who, due to their underlying disease, require immunomodulatory treatment during the development of the study. 9) Subjects with tattoos in the deltoid region on both arms. 10) Decompensated chronic diseases that limit vaccination according to criteria clinical. 11) Subjects with unstabilized malignant disease or who are receiving oncospecific treatment (cytostatics and / or radiotherapy) during the time of the study or have been receiving it in the last three months. 12) HIV positive subjects with detectable viral load, history of opportunistic infection or CD4 less than 200 copies. 13) Pregnancy, puerperium or lactation.
Type of population:
Adults
Type of participant:
Healthy volunteers
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Prevention
Allocation:
Randomized trial
Masking:
Double Blind
Control group:
Uncontrolled
Study design:
Parallel
Phase:
2
Target sample size:
1166
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Beatriz
Last Name:
Paredes Moreno
Specialty:
Pharmaceutical Sciences
Affiliation:
Finlay Vaccine Institute
Postal Address:
21 avenue between 198 and 200 Atabey, Playa
City:
Havana
País:
Cuba
Zip Code:
11600
Telephone:
+53-72718331
Email :
bparedes@finlay.edu.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Meiby
Middle Name:
de la Caridad
Last Name:
Rodriguez Gonzalez
Specialty:
First Degree Specialist in Integral General Medicine. Master in Epidemiology
Affiliation:
Finlay Vaccine Institute
Postal Address:
21 avenue between 198 and 200 Atabey, Playa
City:
Havana
País:
Cuba
Zip Code:
11600
Telephone:
+53-72718331
Email :
mcrodriguez@finlay.edu.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
University of Medical Sciences, Cienfuegos
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
20/07/2021
Postal address of Ethic Committee :
Calle 51 A y Ave. 5 de Septiembre. Municipio Cienfuegos. Provincia Cienfuegos, Cuba
Telephone:
+53-55189034
Correo electrónico:
rectora-ucmcfg@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
30/09/2022
Date of available results:
30/12/2022
Date of first publication:
29/04/2023
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000385
Date of Registration in Primary Registry:
23/07/2021
Record Verification Date:
2021/08/09
Next update date:
2022/08/09
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos